Clearstead Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Clearstead Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-365	Closed	-$39.2K	–	1455
2023 Q1	$39.2K	Buy	+365	New	+$42K	﹤0.01%	714

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Clearstead Advisors's RXDX Position: Q2 2023 in Review

Clearstead Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 365 shares — an estimated $39.2K sold.

Clearstead Advisors first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $39.2K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Clearstead Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Clearstead Advisors sold 365 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $39.2K.
Clearstead Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Clearstead Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $39.2K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Clearstead Advisors's 13F filing for Q2 2023, filed 7 Aug 2023.